Initial experience of vericiguat treatment in patients with heart failure and high risk of decompensation.

Back

HFA Premium Access

Initial experience of vericiguat treatment in patients with heart failure and high risk of decompensation.

Session: ePosters in chronic heart failure - pharmacotherapy 5

Topic: Pharmacotherapy

Speaker: Doctor M. Groba Marco (Las Palmas de Gran Canaria, ES)

Event: Heart Failure 2024

Congress Presentation

Add to my library

About the speaker

Doctor Maria Del Val Groba Marco

Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria (Spain)

0 follower

7 more presentations in this session

Clinical practice associated with 6-month use of patiromer in patients with heart failure

Speaker: Doctor I. ARAUJO (Lisbon, PT)

Remote monitoring in a virtual ward safely facilitates the rapid up-titration of prognostic medication for heart failure with reduced ejection fraction patients

Speaker: Doctor A. Kirupananthavel (London, GB)

Single centre 3-year experience in intermittent levosimendan infusion

Speaker: Doctor F. Gerardo (Amadora, PT)

SGLT2i on transthyretin amyloid cardiomyopathy - a new drug for an under-recognized cardiomyopathy

Speaker: Mr D. Inacio Cazeiro (Lisbon, PT)

SGLT2 inhibitors impact on loop diuretic requirement in a community heart failure cohort

Speaker: Doctor M. Killian (Dublin, IE)

Access the full session

ePosters in chronic heart failure - pharmacotherapy 5

Speakers: Doctor M. Groba Marco, Doctor I. ARAUJO, Doctor A. Kirupananthavel, Doctor F. Gerardo, Mr D. Inacio Cazeiro...

Access

About the event

Heart Failure 2024

11 May - 14 May 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources